News|Videos|October 21, 2020

Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target

Elevated lipoprotein A is a genetically determined independent risk factor for CVD, affecting up to 30% of the population. Phase 3 trials for the first treatment are underway.

________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.

His research activities include atherosclerosis, lipid apheresis, vascular inflamation and hemorheology. He has participated in numerous clinical trials related to dyslipidemia, obesity, hypertension, and diabetes. His clinical activities involve the treatment and diagnosis of atherosclerosis and cardiovascular disease.

Enhance your clinical practice with the Patient Care newsletter, offering the latest evidence-based guidelines, diagnostic insights, and treatment strategies for primary care physicians.

Subscribe Now!

Expert Update on Lp(a): Dr Patrick Moriarty Explains the Next CVD Target

________________________________________________________________Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.

Newsletter

Related Content

Finger-Prick Test Shows Promise for Alzheimer Disease Biomarker Screening

Digital Screening Tool Duo Shows Promise for ADRD Detection in Primary Care: Daily Dose

COVID-19 Vaccination Linked to Lower Risk of Severe Outcomes in Pregnancy Across Delta and Omicron Periods

Tapinarof Cream 1% Shows Early, Durable Response in Children With Atopic Dermatitis: Daily Dose

FDA Accepts Supplemental Application for Teplizumab to Delay Stage 3 Type 1 Diabetes in Children Aged 1 Year and Older

Latest CME

Show Me the Data™: Personalizing First-Line and Maintenance Therapy in HER2+ Metastatic Breast Cancer to Extend Survival and Elevate Quality of Life

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | New York

Community Oncology Connections™: DLL3-Targeting Bispecific Antibodies for Small Cell Lung Cancer – From Innovation to Practice | Iowa

Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP inhibition in Triple-Negative Breast Cancer

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Wisconsin

Community Oncology Connections™: Beyond the Basics—Revolutionizing Advanced Prostate Cancer Management With PSMA-Targeted Therapies | Texas

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Nevada

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Indiana

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Arkansas

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | Tennessee

Medical Crossfire™: Navigating the Expanding Arsenal of Endocrine Therapies for HR+/HER2- Metastatic Breast Cancer – How Can PROTAC ER Degradation Shift the Standard?

Community Oncology Connections™: Optimizing SCLC Treatment Strategies and Managing Adverse Events Across Disease Stages | South Carolina

Personalized Management in NSCLC: Strategies for Early Detection, Molecular Testing, and Targeted Therapies | Kansas

Mastering Advances in Managing Unresectable and Metastatic NSCLC—Immunotherapy, Targeted Therapies, and Emerging Strategies

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

(CME Track) Visionary Approaches: Rethinking Therapeutic and Interventional Glaucoma Management

(CME Track) Revolutionizing nAMD and DME Management: Collaborative Strategies in the Age of Durable Treatments

A New Era in NMOSD Treatment: Optimizing Therapeutic Transitions and Reducing Patient Burden

(CME Track) Expanding Horizons in Toric IOLs: Translating Technological Advances Into Improved Patient Outcomes

(CME Track) The TED Perspective: A Multidisciplinary Approach to Thyroid Eye Care

Updates and Innovations in Nonopioid Pain Management Strategies for Breast Cancer Patients Postsurgical Intervention

20th Annual Controversies in Modern Eye Care

Optimizing Today and Looking to Tomorrow in Metastatic CRPC—Homing in on EZH2

(COPE Track) Clinical Consultations™: Framing a New Approach to Geographic Atrophy Management – Expert Insights into Recent Developments

Addressing Unmet Needs in HER2+ Metastatic BTC

Upstate New York Hematology & Hematologic Oncology Conference: A Review of the 67th ASH Annual Meeting

The Role of the Multidisciplinary Care Team in the Diagnosis and Management of Acute Hepatic Porphyria

Case-by-Case: Application of HIF-PHIs for the Treatment of Anemia in Patients With CKD

Cases & Conversations™: Expert Perspectives on Leveraging Recent Advances to Transform SCLC Treatment

(COPE Track) Rapid Reviews in Retina™: Emerging Updates from Winter 2025 – Addressing the Wealth of New Data in Treatments for nAMD and DME

Shaping Surgical Pathways: Revolutionizing Breast Cancer Care With Genetic Testing and Targeted Treatment

29th Annual International Congress on Hematologic Malignancies: Focus on Leukemias, Lymphomas, and Myeloma

10th Annual School of Gastrointestinal Oncology

Community Practice Connections™: Exploring Emerging Next-Generation Endocrine Therapies in ER+/HER2- Breast Cancer – Evaluating the Potential of Future of Treatment

Living With X-Linked Retinitis Pigmentosa: What We Can Learn From a Patient’s Experience

Community Practice Connections™: Translating Evidence to Clinical Practice in Early-Stage HR+, HER2- Breast Cancer

Innovations in HR+/HER2– Metastatic Breast Cancer: Advancing Care Through PROTAC ER Degradation

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Community Practice Connections™: 21st Annual International Symposium on Melanoma and Other Cutaneous Malignancies

(CME Track) Collaborative Community Connections™: Mastering the Management of nAMD and DME Through Therapeutic Innovation

Navigating the Glaucoma Therapeutic and Surgical Landscape: From Conventional to Cutting-Edge

Show Me Your Care Plan!™ Insights for Oncology Nurses: Integrating Recent Developments to Improve Outcomes for Patients With Platinum-Resistant Ovarian Cancer

Cases and Conversations™: A Horizon View of Continuous Monitoring Systems for Diabetes Management

(CME Track) The Neural Network: Exploring The Role of Neuromodulation in Dry Eye Disease Management

Expert Illustrations and Commentaries™: Managing Hyperphosphatemia in CKD—A Closer Look at the Paracellular Pathway

(CME Track) Toric IOLs Unleashed: From Technological Progress to Patient Success

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

(CME Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Understanding the Impact of Advances in Treatment for DME and DR

(COPE Track) Clinical Case Connections: Expert Insights on Applying Therapeutic Innovations in nAMD

Show Me Your Care Plan!™ Insights for Oncology Nurses on Comprehensive SCLC Treatment and Care Strategies

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

PER Podcast™: Maximizing the Multidisciplinary Care Outcomes of Patients with Amyotrophic Lateral Sclerosis (ALS)

PER Podcast™: Best Strategies for Approaching the Diagnosis of Amyotrophic Lateral Sclerosis (ALS)

(COPE Credit) Navigating Pharmacological Presbyopia Treatment for Enhanced Patient Care

Expert Illustrations & Commentaries™: Visualizing the Role of the Complement Pathway in Paroxysmal Nocturnal Hemoglobinuria

Addressing Healthcare Inequities: Detecting and Managing the Uncommon – Hemophilia in Women

Breaking the 𝘋𝘦𝘮𝘰𝘥𝘦𝘹 Blepharitis Cycle: The Importance of Early Intervention

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

(CME Credit) Advancing Outcomes in Limited-Stage Small Cell Lung Cancer: From Evidence to Practice

(CME Track) Small Mites, Big Impact: Revolutionizing Demodex Blepharitis Care

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Medical Crossfire®: The Precision Path for HER2 and TROP2-Targeted Treatments in Non–Small Cell Lung Cancer

Breast Cancer Tumor Board®: Advancing Care in Metastatic Breast Cancer - The Evolving Role of Antibody-Drug Conjugates

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

10th Annual Live Medical Crossfire®: Hematologic Malignancies

Burst CME: Managing Fluid Overload in Patients with Chronic Kidney Disease (Part 1)

________________________________________________________________
Patrick M Moriarty, MD, is professor of medicine and director of clinical pharmacology and the Atherosclerosis/Lipoprotein-Apheresis Center at the University of Kansas Medical Center, in Kansas City.